Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20233644 | 0.98 | NAMPT (0.41) | NAMPTAKT1TSHRHPGDGAA | |
| SCHEMBL20330072 | 0.92 | NAMPT (0.39) | NAMPTAKT1TSHRHPGDGAA | |
| SCHEMBL20330007 | 0.88 | TSHR (0.39) | NAMPTAKT1TSHRHPGDGAA | |
| SCHEMBL20322406 | 0.88 | TSHR (0.39) | NAMPTAKT1TSHRHPGDGAA | |
| SCHEMBL23664707 | 0.86 | ALDH1A1 (0.44) | NAMPTTSHRGAAKDM4EALDH1A1 | |
| SCHEMBL20323702 | 0.86 | ALDH1A1 (0.44) | NAMPTTSHRGAAKDM4EALDH1A1 | |
| SCHEMBL20231530 | 0.86 | TSHR (0.40) | NAMPTAKT1TSHRHPGDGAA | |
| SCHEMBL21341880 | 0.81 | TSHR (0.38) | NAMPTAKT1TSHRHPGDKDM4E | |
| SCHEMBL354459 | 0.80 | NAMPT (0.40) | NAMPTAKT1TSHRHPGDGAA | |
| SCHEMBL31053510 | 0.80 | TPI1 (0.45) | NAMPTAKT1TSHRHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | YALE UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | YALE UNIVERSITY | 2019-09-12 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | NAMPT 4798/4885AKT1 1538/4885TSHR 2220/4885 |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | NAMPT 4168/4885AKT1 1525/4885TSHR 3794/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | NAMPT 4757/4885AKT1 472/4885TSHR 3456/4885 |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | BTK, CBL, CRBN | NAMPT 4385/4885AKT1 527/4885TSHR 4036/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | NAMPT 4168/4885AKT1 1525/4885TSHR 3794/4885 |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | NAMPT 4385/4885AKT1 527/4885TSHR 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.